MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Actinium Pharmaceuticals ROE Ratio 2011-2026 | ATNM
Annual ROE Ratio Actinium Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -432.56 | -116.74 | -134.19 | -49.66 | -33.69 | -36.23 | -387.97 | -268.4 | -194.58 | -135.06 | -95.68 | 1284.12 | 690.83 | -729.83 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1284.12 | -729.83 | -45.69 |
Quarterly ROE Ratio Actinium Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -165.71 | -158.76 | -148.48 | -75.94 | -106.41 | -106.59 | -109.29 | -78.36 | -91.65 | -74.49 | -55.82 | -30.68 | -38.68 | -33.39 | -29.69 | -21.76 | -30.79 | -31.83 | -33.13 | -25.82 | -142.74 | -250.63 | -332.16 | -306.45 | -376.21 | -329.06 | -295.17 | -196.69 | -242.94 | -219.43 | -215.85 | -156.81 | -193.46 | -183.85 | -169.04 | -97.88 | -115.84 | -97.15 | -94.33 | -65.92 | 250.18 | 584.23 | 435.36 | 1001.88 | 1092.99 | 868.01 | 1229.36 | 313.81 | 50.86 | -303.21 | -618.12 | -1129.18 | -1129.58 | -862.46 | -745.58 | -0.4 | 4.17 | -19.51 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1229.36 | -1129.58 | -77.69 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 21.77 | 1.68 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-5.9 | $ 0.92 | 3.05 % | $ 6.76 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.44 | 2.16 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
7.51 | $ 2.02 | 5.76 % | $ 420 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Galectin Therapeutics
GALT
|
24.11 | $ 2.42 | 3.65 % | $ 155 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Heron Therapeutics
HRTX
|
-140.9 | $ 1.26 | 6.3 % | $ 210 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
ImmuCell Corporation
ICCC
|
-3.84 | $ 8.28 | -0.84 % | $ 74.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
InflaRx N.V.
IFRX
|
-43.64 | $ 1.53 | 3.38 % | $ 152 M | Germany |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 103.31 | -2.04 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.14 | 1.47 % | $ 443 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 23.57 | 1.33 % | $ 3 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-41.02 | $ 1.39 | 0.72 % | $ 235 M | France |
 |
Inventiva S.A.
IVA
|
-30.23 | $ 5.18 | 0.49 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
286.68 | $ 0.36 | -8.39 % | $ 840 K | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.46 | 1.04 % | $ 389 M | Britain |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
KalVista Pharmaceuticals
KALV
|
4039.99 | $ 20.08 | 2.29 % | $ 1.08 B | Britain |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.99 | 2.05 % | $ 4.92 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-132.24 | $ 12.42 | 1.26 % | $ 1.65 B |  Australia |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |